Bellevue Group’s Maze Therapeutics MAZE Stock Holding History

Bellevue Group’s Portfolio MAZE Stock Details MAZE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-887,708	Closed	-$36.8M	–	195
2025 Q4	$36.8M	Buy	+887,708	New	+$30.5M	0.7%	34

Other funds holding MAZE

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Janus Henderson Group

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Bellevue Group's MAZE Position: Q1 2026 in Review

Bellevue Group sold out of Maze Therapeutics (MAZE) in Q1 2026, closing a stake of 887,708 shares — an estimated $36.8M sold.

Bellevue Group first reported a position in MAZE in Q4 2025 and held it in 1 quarter. The position peaked at $36.8M in Q4 2025. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

Bellevue Group reported no remaining Maze Therapeutics position as of Q1 2026 after selling out during the quarter.
Bellevue Group sold 887,708 Maze Therapeutics shares in Q1 2026, an estimated $36.8M.
Bellevue Group first reported a position in Maze Therapeutics in Q4 2025 and held it in 1 quarter.
Bellevue Group's Maze Therapeutics position peaked at $36.8M in Q4 2025.
165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.